Dyne Therapeutics Inc (DYN)
28.50
+1.72
(+6.42%)
USD |
NASDAQ |
Mar 27, 16:00
28.90
+0.40
(+1.40%)
After-Hours: 07:34
Dyne Therapeutics Enterprise Value: 2.213B for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 2.213B |
March 26, 2024 | 2.072B |
March 25, 2024 | 2.013B |
March 22, 2024 | 2.191B |
March 21, 2024 | 2.268B |
March 20, 2024 | 2.164B |
March 19, 2024 | 2.132B |
March 18, 2024 | 2.031B |
March 15, 2024 | 2.171B |
March 14, 2024 | 2.064B |
March 13, 2024 | 2.153B |
March 12, 2024 | 2.098B |
March 11, 2024 | 1.971B |
March 08, 2024 | 1.939B |
March 07, 2024 | 2.044B |
March 06, 2024 | 2.072B |
March 05, 2024 | 1.997B |
March 04, 2024 | 2.148B |
March 01, 2024 | 2.264B |
February 29, 2024 | 2.082B |
February 28, 2024 | 1.905B |
February 27, 2024 | 1.874B |
February 26, 2024 | 1.829B |
February 23, 2024 | 1.727B |
February 22, 2024 | 1.696B |
Date | Value |
---|---|
February 21, 2024 | 1.708B |
February 20, 2024 | 1.723B |
February 16, 2024 | 1.737B |
February 15, 2024 | 1.793B |
February 14, 2024 | 1.841B |
February 13, 2024 | 1.753B |
February 12, 2024 | 1.851B |
February 09, 2024 | 1.826B |
February 08, 2024 | 1.722B |
February 07, 2024 | 1.618B |
February 06, 2024 | 1.658B |
February 05, 2024 | 1.653B |
February 02, 2024 | 1.585B |
February 01, 2024 | 1.668B |
January 31, 2024 | 1.614B |
January 30, 2024 | 1.597B |
January 29, 2024 | 1.574B |
January 26, 2024 | 1.595B |
January 25, 2024 | 1.330B |
January 24, 2024 | 1.254B |
January 23, 2024 | 1.256B |
January 22, 2024 | 1.191B |
January 19, 2024 | 1.145B |
January 18, 2024 | 1.193B |
January 17, 2024 | 1.229B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-97.94M
Minimum
Jun 02 2022
2.268B
Maximum
Mar 21 2024
475.09M
Average
421.49M
Median
Sep 20 2022
Enterprise Value Benchmarks
First Wave BioPharma Inc | 4.528M |
ABVC BioPharma Inc | 13.74M |
NexImmune Inc | -3.170M |
Voyager Therapeutics Inc | 288.24M |
Applied Therapeutics Inc | 675.74M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -66.64M |
Total Expenses (Quarterly) | 67.69M |
EPS Diluted (Quarterly) | -1.09 |
Earnings Yield | -13.82% |